Key Highlights

  • Pre-market quotes on Friday, November 13, 2026 showed the shares at USD 0.85, down 19.73%, implying a prior close near USD 1.06 (calculated), though no company statement explaining the drop turned up.
  • ASE, a semiconductor customer, has received 1,400 AI Nose units as part of a USD 2.1 million agreement spanning three years, per a September 2026 update.
  • Ainos confirmed the VELDONA technology transfer on September 29, 2026, which set off an initial USD 600,000 license payment, with further payments linked to milestones.
  • One published review put cash at about USD 1.4 million on June 30, 2026 against roughly USD 1.45 million of operating cash used in the second quarter, a figure not yet checked against the filing.

A 19.73% Slide Without a Fresh Company Announcement

Ainos (NASDAQ:AIMD) was quoted 19.73% lower at USD 0.85 pre-market on Friday, November 13, 2026. Nothing dated November 11 to November 13 in the way of a company statement, filing or analyst note has surfaced that could account for the decline. Quarterly results for the third quarter are anticipated in November; calendars point to a window of November 11 to November 13, yet no date appeared in the company material reviewed. A published review placed the shares near USD 0.63 on October 30, so the prior close near USD 1.06 (calculated) would imply a sharp climb before this fall. Narrow trading Volume can inflate moves of this kind, so the decline reads as price movement itself, not a response to any company development, until a cause is confirmed.

AI Nose Deliveries and the VELDONA License Terms

Ainos (NASDAQ:AIMD) describes itself as a dual-platform Business that combines AI-based smell technology with immune therapeutics. The AI Nose converts scent into machine-readable data for use in semiconductors, robotics and smart manufacturing, and the 1,400 units delivered to ASE fall under a three-year USD 2.1 million contract. The BioPhoenix VELDONA license, signed in late September, opens a route to a collaboration framework worth up to USD 10 million. The VELDONA line, built on low-dose oral interferon, yielded an initial USD 600,000 payment once its technology transfer went through. Nothing in the reviewed material points to additional AI Nose purchases, and the potential sums are not assured revenue. Spread over three years, the ASE deal comes to roughly USD 700,000 annually (calculated), a modest figure beside the 2025 loss of USD 14.77 million.

Tiny Revenue, Thin Cash and Funding Needs Ahead

Market data on October 21, 2026 listed 2025 Revenue of USD 124,157 and a net loss of USD 14.77 million, plus a Market Value near USD 6.65 million on 7.38 million shares. The 52-week range was USD 0.80 to USD 4.02 on that date. Cash of about USD 1.4 million at June 30 is thin beside roughly USD 1.45 million of quarterly operating cash burn, which points to fresh funding. A company this size often turns to share sales, which dilute current holders. Ahead lie the third-quarter report, the cash position after the USD 600,000 payment, and whether any financing arrives. The shares trade under USD 1, so listing pressure exists, although the reviewed material showed no deficiency notice, and a reverse split is a frequent fix at such prices.

Where Things Stand

Very little company news explains the move. Nothing located accounts for the 19.73% pre-market drop at Ainos (NASDAQ:AIMD), so it reads as a Reversal after a rise from about USD 0.63 on October 30 to near USD 1.06 (calculated), possibly ahead of third-quarter results. Some deliveries and license milestones have been reached, yet revenue is minimal, cash of about USD 1.4 million at June 30 leaves little room, and dilution remains a live risk. Items to monitor are the quarterly report, any new funding and whether more AI Nose orders arrive. Without a company statement, the reason for the move remains unverified.